@article{10670,
  keywords = {Administration, Inhalation, Adrenal Cortex Hormones, Adrenergic beta-2 Receptor Agonists/adverse effects, *Asthma/drug therapy, Beclomethasone/therapeutic use, Budesonide, Formoterol Fumarate Drug Combination/therapeutic use, Formoterol Fumarate/therapeutic use, Humans, Muscarinic Antagonists/therapeutic use, Primary health care, *Pulmonary Disease, Chronic Obstructive/drug therapy, Retrospective Studies, COPD epidemiology, COPD pharmacology, inhaler devices},
  author = {A. Czira and V. Banks and G. Requena and R. Wood and T. Tritton and R. Wild and C. Compton and M. Duarte and A. Ismaila},
  title = {Characterisation of patients with chronic obstructive pulmonary disease initiating single-device inhaled corticosteroids/long-acting β(2)-agonist dual therapy in a primary care setting in England},
  year = {2022},
  journal = {BMJ Open Respir Res},
  volume = {9},
  edition = {2022/09/29},
  number = {1},
  isbn = {2052-4439},
  doi = {10.1136/bmjresp-2022-001243},
  note = {2052-4439
Czira, Alexandrosz
Banks, Victoria
Requena, Gema
Wood, Robert
Tritton, Theo
Wild, Rosie
Compton, Chris
Duarte, Maria
Ismaila, Afisi S
Journal Article
Research Support, Non-U.S. Gov't
BMJ Open Respir Res. 2022 Sep;9(1):e001243. doi: 10.1136/bmjresp-2022-001243.},
  language = {eng},
}